Tammela et al reported that the inhibition of VEGFR-3 with a monoclonal antibody reduced vascular sprouting, vascular branches and endothelial cell proliferation during embryonic development and tumor growth (14), which suggests that VEGFR-3 is a novel target in the treatment of CNV. Here, FLT4 is linked to neoplasm.